Japan Nuclear Imaging Market Size (2024 - 2029)

The Japan Nuclear Imaging Devices Market is projected to experience growth due to several key factors. The increasing prevalence of cancer and cardiovascular disorders, coupled with advancements in technology and the expanding applications of nuclear medicine and imaging, are driving the market's expansion. The market's growth is further supported by the rising concerns over public health issues, such as coronary heart disease and hypertension, which are prevalent in the Japanese population. These health challenges, along with the high incidence of end-stage kidney failure, are expected to contribute significantly to the market's development during the forecast period.

Market Size of Japan Nuclear Imaging Industry

Japan Nuclear Imaging Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 325.42 Million
Market Size (2029) USD 406.51 Million
CAGR (2024 - 2029) 4.55 %

Major Players

Japan Nuclear Imaging Market Major Players

*Disclaimer: Major Players sorted in no particular order

Japan Nuclear Imaging Market Analysis

The Japan Nuclear Imaging Market size is estimated at USD 325.42 million in 2024, and is expected to reach USD 406.51 million by 2029, growing at a CAGR of 4.55% during the forecast period (2024-2029).

Certain factors that are driving the market growth include the rise in prevalence of cancer and cardiac disorders, increase in technological advancements, growth in the applications of nuclear medicine and imaging.

After being ranked the topmost cause of life-loss in the last century, stroke is now the third-ranked cause of death in Japan, following cancer and heart disease. According to the 2018 article, 'Lifestyle and cardiovascular disease in Japan', the recent trend of rising CHD (coronary heart disease) prevalence among the urban population is a cause for serious concern, as a potential source of forthcoming problems for public health as well as clinical practice in Japan. Moreover, due to the association between lifestyle and CVD (cardiovascular disease), higher sodium, lower calcium, and lower animal protein content in the diet, along with higher alcohol consumption, may account for the higher prevalence of hypertension and higher risk of stroke in the Japanese population than for western population at same BMI levels. According to the latest OECD data, in Japan, patients with end-stage kidney failure (ESKF), often caused by diabetes and hypertension, are the highest in the OECD at 238 per 100,000 population while the average is 101. Thus, the increasing prevalence of cancer, along with certain cardiovascular diseases, is expected to propel the growth of the nuclear imaging market in Japan.

Japan Nuclear Imaging Industry Segmentation

As per the scope of the report, nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac and neurological disorders. 

The Japanese Nuclear Imaging Market is Segmented by Product (Equipment and Radioisotope (SPECT Radioisotopes (Technetium-99m (TC-99m), Thallium-201 (TI-201), Gallium (Ga-67), Iodine (I-123), and Other SPECT Radioisotopes) and PET Radioisotopes (Fluorine-18 (F-18), Rubidium-82 (RB-82), and Other PET Radioisotopes), Application (SPECT Applications (Orthopedics, Thyroid, Cardiology, and Other SPECT Applications) and PET Applications (Oncology, Oncology, Neurology, and Other PET Applications). The report offers the value (in USD million) for the above segments.

Product
Equipment
Radioisotope
SPECT Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Other SPECT Radioisotopes
PET Radioisotopes
Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
Application
SPECT Applications
Orthopedics
Thyroid
Cardiology
Other SPECT Applications
PET Applications
Oncology
Cardiology
Neurology
Other PET Applications
Need A Different Region Or Segment?
Customize Now

Japan Nuclear Imaging Market Size Summary

The Japan Nuclear Imaging Devices Market is poised for growth, driven by the increasing prevalence of cancer and cardiovascular diseases, alongside advancements in technology and the expanding applications of nuclear medicine. The market is expected to experience a steady rise over the forecast period, supported by the growing demand for early diagnostics and treatment options. The oncology segment, in particular, is anticipated to capture a significant share due to the rising burden of cancer and the enhanced use of radioisotopes for diagnosis and treatment. The integration of artificial intelligence in nuclear medicine is further expected to bolster market growth by improving diagnostic accuracy and treatment planning.

The market landscape is characterized by moderate competition, with key players such as ATOX CO. Ltd, Bracco Imaging SpA, CANON INC., and GE Healthcare actively participating in strategic collaborations and technological advancements. These companies are focusing on expanding their product offerings and enhancing their research and development capabilities to meet the growing demand for nuclear imaging devices. The increasing number of chronic diseases and the need for effective diagnostic tools are driving the demand for nuclear imaging equipment across various medical applications, including cardiology and orthopedics. As a result, the market is set to expand, supported by both technological innovations and strategic partnerships among industry players.

Explore More

Japan Nuclear Imaging Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Prevalence of Cancer and Cardiac Disorders

      2. 1.2.2 Increase in Technological Advancements

      3. 1.2.3 Growth in the Applications of Nuclear Medicine and Imaging

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Techniques

      2. 1.3.2 Short Half-life of Radiopharmaceuticals

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 Product

      1. 2.1.1 Equipment

      2. 2.1.2 Radioisotope

        1. 2.1.2.1 SPECT Radioisotopes

          1. 2.1.2.1.1 Technetium-99m (TC-99m)

          2. 2.1.2.1.2 Thallium-201 (TI-201)

          3. 2.1.2.1.3 Gallium (Ga-67)

          4. 2.1.2.1.4 Iodine (I-123)

          5. 2.1.2.1.5 Other SPECT Radioisotopes

        2. 2.1.2.2 PET Radioisotopes

          1. 2.1.2.2.1 Fluorine-18 (F-18)

          2. 2.1.2.2.2 Rubidium-82 (RB-82)

          3. 2.1.2.2.3 Other PET Radioisotopes

    2. 2.2 Application

      1. 2.2.1 SPECT Applications

        1. 2.2.1.1 Orthopedics

        2. 2.2.1.2 Thyroid

        3. 2.2.1.3 Cardiology

        4. 2.2.1.4 Other SPECT Applications

      2. 2.2.2 PET Applications

        1. 2.2.2.1 Oncology

        2. 2.2.2.2 Cardiology

        3. 2.2.2.3 Neurology

        4. 2.2.2.4 Other PET Applications

Japan Nuclear Imaging Market Size FAQs

The Japan Nuclear Imaging Market size is expected to reach USD 325.42 million in 2024 and grow at a CAGR of 4.55% to reach USD 406.51 million by 2029.

In 2024, the Japan Nuclear Imaging Market size is expected to reach USD 325.42 million.

Japan Nuclear Imaging Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)